Literature DB >> 22748208

A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system.

John F Staropoli1, Amel Karaa, Elaine T Lim, Andrew Kirby, Naser Elbalalesy, Stephen G Romansky, Karen B Leydiker, Scott H Coppel, Rosemary Barone, Winnie Xin, Marcy E MacDonald, Jose E Abdenur, Mark J Daly, Katherine B Sims, Susan L Cotman.   

Abstract

Neuronal ceroid lipofuscinosis (NCL) is a genetically heterogeneous group of lysosomal diseases that collectively compose the most common Mendelian form of childhood-onset neurodegeneration. It is estimated that ∼8% of individuals diagnosed with NCL by conservative clinical and histopathologic criteria have been ruled out for mutations in the nine known NCL-associated genes, suggesting that additional genes remain unidentified. To further understand the genetic underpinnings of the NCLs, we performed whole-exome sequencing on DNA samples from a Mexican family affected by a molecularly undefined form of NCL characterized by infantile-onset progressive myoclonic epilepsy (PME), vision loss, cognitive and motor regression, premature death, and prominent NCL-type storage material. Using a recessive model to filter the identified variants, we found a single homozygous variant, c.550C>T in KCTD7, that causes a p.Arg184Cys missense change in potassium channel tetramerization domain-containing protein 7 (KCTD7) in the affected individuals. The mutation was predicted to be deleterious and was absent in over 6,000 controls. The identified variant altered the localization pattern of KCTD7 and abrogated interaction with cullin-3, a ubiquitin-ligase component and known KCTD7 interactor. Intriguingly, murine cerebellar cells derived from a juvenile NCL model (CLN3) showed enrichment of endogenous KCTD7. Whereas KCTD7 mutations have previously been linked to PME without lysosomal storage, this study clearly demonstrates that KCTD7 mutations also cause a rare, infantile-onset NCL subtype designated as CLN14.
Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748208      PMCID: PMC3397260          DOI: 10.1016/j.ajhg.2012.05.023

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  35 in total

1.  Cullin-3 regulates late endosome maturation.

Authors:  Jatta Huotari; Nathalie Meyer-Schaller; Michaela Hubner; Sarah Stauffer; Nadja Katheder; Peter Horvath; Roberta Mancini; Ari Helenius; Matthias Peter
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

2.  Novel mutation in potassium channel related gene KCTD7 and progressive myoclonic epilepsy.

Authors:  Birgit Krabichler; Kevin Rostasy; Matthias Baumann; Daniela Karall; Sabine Scholl-Bürgi; Christoph Schwarzer; Kurt Gautsch; Ana Spreiz; Dieter Kotzot; Johannes Zschocke; Christine Fauth; Edda Haberlandt
Journal:  Ann Hum Genet       Date:  2012-05-21       Impact factor: 1.670

3.  The functional spectrum of low-frequency coding variation.

Authors:  Gabor T Marth; Fuli Yu; Amit R Indap; Kiran Garimella; Simon Gravel; Wen Fung Leong; Chris Tyler-Smith; Matthew Bainbridge; Tom Blackwell; Xiangqun Zheng-Bradley; Yuan Chen; Danny Challis; Laura Clarke; Edward V Ball; Kristian Cibulskis; David N Cooper; Bob Fulton; Chris Hartl; Dan Koboldt; Donna Muzny; Richard Smith; Carrie Sougnez; Chip Stewart; Alistair Ward; Jin Yu; Yali Xue; David Altshuler; Carlos D Bustamante; Andrew G Clark; Mark Daly; Mark DePristo; Paul Flicek; Stacey Gabriel; Elaine Mardis; Aarno Palotie; Richard Gibbs
Journal:  Genome Biol       Date:  2011-09-14       Impact factor: 13.583

4.  Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.

Authors:  Lenka Nosková; Viktor Stránecký; Hana Hartmannová; Anna Přistoupilová; Veronika Barešová; Robert Ivánek; Helena Hůlková; Helena Jahnová; Julie van der Zee; John F Staropoli; Katherine B Sims; Jaana Tyynelä; Christine Van Broeckhoven; Peter C G Nijssen; Sara E Mole; Milan Elleder; Stanislav Kmoch
Journal:  Am J Hum Genet       Date:  2011-08-04       Impact factor: 11.025

Review 5.  Neurological potassium channelopathies.

Authors:  M Benatar
Journal:  QJM       Date:  2000-12

Review 6.  Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.

Authors:  K E Wisniewski; N Zhong; M Philippart
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

7.  Familial Kufs' disease presenting as a progressive myoclonic epilepsy.

Authors:  B Sadzot; M Reznik; J E Arrese-Estrada; G Franck
Journal:  J Neurol       Date:  2000-06       Impact factor: 4.849

8.  Progressive myoclonic epilepsy-associated gene KCTD7 is a regulator of potassium conductance in neurons.

Authors:  Régis Azizieh; David Orduz; Patrick Van Bogaert; Tristan Bouschet; Wendy Rodriguez; Serge N Schiffmann; Isabelle Pirson; Marc J Abramowicz
Journal:  Mol Neurobiol       Date:  2011-06-28       Impact factor: 5.682

Review 9.  Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.

Authors:  Maria Kousi; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.700

10.  Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis.

Authors:  Bruno A Benitez; David Alvarado; Yefei Cai; Kevin Mayo; Sumitra Chakraverty; Joanne Norton; John C Morris; Mark S Sands; Alison Goate; Carlos Cruchaga
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

View more
  39 in total

1.  Progressive myoclonic epilepsy-associated gene Kctd7 regulates retinal neurovascular patterning and function.

Authors:  Jonathan Alevy; Courtney A Burger; Nicholas E Albrecht; Danye Jiang; Melanie A Samuel
Journal:  Neurochem Int       Date:  2019-06-06       Impact factor: 3.921

Review 2.  Future perspectives: Moving towards NCL treatments.

Authors:  Susan L Cotman; Sara E Mole; Romina Kohan
Journal:  Biochim Biophys Acta       Date:  2015-04-07

Review 3.  Lysosomal diseases: diagnostic update.

Authors:  Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

Review 4.  Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  Sara E Mole; Susan L Cotman
Journal:  Biochim Biophys Acta       Date:  2015-05-27

Review 5.  Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies.

Authors:  Julia Oyrer; Snezana Maljevic; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou; Christopher A Reid
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

Review 6.  Neuronal ceroid lipofuscinosis: impact of recent genetic advances and expansion of the clinicopathologic spectrum.

Authors:  Susan L Cotman; Amel Karaa; John F Staropoli; Katherine B Sims
Journal:  Curr Neurol Neurosci Rep       Date:  2013-08       Impact factor: 5.081

7.  NCL diseases - clinical perspectives.

Authors:  Angela Schulz; Alfried Kohlschütter; Jonathan Mink; Alessandro Simonati; Ruth Williams
Journal:  Biochim Biophys Acta       Date:  2013-04-17

Review 8.  The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications.

Authors:  Pascal Genschik; Izabela Sumara; Esther Lechner
Journal:  EMBO J       Date:  2013-08-02       Impact factor: 11.598

Review 9.  Lysosomal storage diseases--the horizon expands.

Authors:  Rose-Mary Naaman Boustany
Journal:  Nat Rev Neurol       Date:  2013-08-13       Impact factor: 42.937

10.  Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.

Authors:  Romina Kohan; María Noelia Carabelos; Winnie Xin; Katherine Sims; Norberto Guelbert; Inés Adriana Cismondi; Patricia Pons; Graciela Irene Alonso; Mónica Troncoso; Scarlet Witting; David A Pearce; Raquel Dodelson de Kremer; Ana María Oller-Ramírez; Inés Noher de Halac
Journal:  Gene       Date:  2012-12-22       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.